Department of Pathology and Committee on Immunology, University of Chicago, Chicago, IL 60637, USA.
Cell Mol Immunol. 2012 Jan;9(1):20-6. doi: 10.1038/cmi.2011.49. Epub 2011 Nov 21.
Tumor metastases and relapse are the major causes of morbidity and mortality in cancer. Although surgery, chemotherapy and/or radiation therapy can typically control primary tumor growth, metastatic and relapsing tumors are often inaccessible or resistant to these treatments. An adaptive immune response can be generated during these conventional treatments of the primary tumor, and presumably both the primary tumor and secondary metastases share many of the same or similar antigenic characteristics recognized by the immune system. Thus, when established, this response should be able to control metastatic growth and tumor relapse. This review summarizes the mechanisms by which antitumor immune responses are generated, and recent findings supporting the hypothesis that many therapies targeting primary tumors can generate antitumor adaptive immune responses to prevent metastases and tumor relapse.
肿瘤转移和复发是癌症发病率和死亡率的主要原因。尽管手术、化疗和/或放疗通常可以控制原发性肿瘤的生长,但转移性和复发性肿瘤通常无法触及或对这些治疗具有耐药性。在原发性肿瘤的这些常规治疗过程中,可以产生适应性免疫反应,并且推测原发性肿瘤和继发性转移瘤具有免疫系统识别的许多相同或相似的抗原特征。因此,一旦建立,这种反应应该能够控制转移性生长和肿瘤复发。这篇综述总结了抗肿瘤免疫反应产生的机制,以及最近的研究结果支持了这样一种假设,即许多针对原发性肿瘤的治疗方法可以产生抗肿瘤适应性免疫反应,以预防转移和肿瘤复发。